Procare Diagnostics is a member of the Impact Medical Strategies group of companies and is developing next generation prostate diagnostic tests to improve the detection and medical management of Prostate Cancer.
Procare has developed a novel biomarker that may improve detection of prostate cancer, better focusing care for patients at highest risk, potentially preventing needless biopsies and saving healthcare cost. Currently we are developing a lab assay and rapid point-of-care (POC) test.
Did you know that in the majority of cases physicians recommend men to undergo prostate biopsy only as a precaution, since existing tests have limitations relative to their accuracy. Poor specificity of existing tests may lead to unnecessary biopsies and prostatectomy, carrying the risks of infection, urinary incontinence, and sexual dysfunction.
Each year 700,000 men could avoid undergoing biopsies if they have access to a more specific and sensitive assay for prostate cancer. Procare is striving to provide the solution for this unmet need. We will offer physicians a novel assay which will be noninvasive (urine specimen), accurate, painless and affordable.